Remedy raises Series B to advance remote stroke surgery robot
Medtech startup Remedy raised Series B funding to advance its remote stroke surgery robot.
Reported by Startup DailyClaims checked against the source, 6 h ago.
ShareWhy it matters
Stroke patients in regional areas could get specialist treatment without travelling to major cities. This saves hours from emergency care.
In Australia. Remedy plans to work with the Australian Stroke Alliance; specialists in major Australian cities could eventually treat patients at regional hospitals using the robot.
Key facts
- US$35 million
- Previous capital raised
- 6 kilometres
- Remote test distance
- August 2025
- Test date
- David Bell, Jake Sganga
- Founders
- Remedy was founded by Bell and Jake Sganga.
- The startup raised funding from US investment firm DCVC and backing from Blackbird, Build Collective, Divergent Capital and KdT Ventures.
- Australia's Hostplus super fund and UC's investment office also invested.
- The N1 robot lets surgeons operate a catheter from far away to treat stroke patients who are hundreds of kilometres away.
- Machine learning software looks at scans and simulates procedures.
- Remedy is seeking US Food and Drug Administration approval.
- A Toronto neurosurgeon tested the N1 in August 2025, performing diagnostic angiograms on patients 6 kilometres away.


